premixed insulin
- Generic Name
- premixed insulin
The Efficacy and Safety of Insulin Degludec/Liraglutide Combination (IDegLira) in Patients With Type 2 Diabetes
Phase 4
Not yet recruiting
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2024-05-10
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 256
- Registration Number
- NCT06408532
Comparison of Two Biphasic Insulin Regimens
Not Applicable
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: Premixed Human Isophane Insulin Suspension + Human Insulin Injection
- First Posted Date
- 2021-01-27
- Last Posted Date
- 2021-01-27
- Lead Sponsor
- Aristotle University Of Thessaloniki
- Target Recruit Count
- 36
- Registration Number
- NCT04726657
Insulins Glargine and gluLisine strAtegy Versus Premixed Insulin strAteGy: a cOmparative Study
Phase 4
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2010-05-12
- Last Posted Date
- 2013-04-04
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 934
- Registration Number
- NCT01121835
- Locations
- 🇨🇴
Investigational Site Number 170003, Bucaramanga, Colombia
🇨🇴Investigational Site Number 170004, Pereira, Colombia
🇨🇳Investigational Site Number 156012, Haikou, China
Insulin Glargine "All to Target" Trial
Phase 4
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2006-10-04
- Last Posted Date
- 2011-05-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 588
- Registration Number
- NCT00384085
- Locations
- 🇺🇸
Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath